{
  "item1": "claims involving Company's patent other intellectual property described Note 19 Legal proceedings—Intellectual property Notes Consolidated Financial Statements included Item 8 Report. Sales Company’s largest product, collectively DARZALEX (daratumumab) DARZALEX FASPRO (daratumumab hyaluronidase-fihj), accounted approximately 13.1% Company's total revenues fiscal 2024. Accordingly, patents related these products believed material Company. Genmab A/S owns two patent families related DARZALEX, Janssen Biotech, Inc.",
  "item7": "divested interest $2.5 billion recorded additional paid-in capital. closing IPO, Johnson & Johnson owned approximately 89.6% total outstanding shares Kenvue Common Stock July 2, 2023, non-controlling interest $1.3 billion associated Kenvue reflected equity attributable non-controlling interests consolidated balance sheet. August 23, 2023, Johnson & Johnson completed disposition additional 80.1% ownership Kenvue Common Stock through exchange offer, which resulted Johnson & Johnson acquiring 190,955,436 shares Company’s common stock exchange 1,533,830,450 shares Kenvue Common Stock. $31.4 billion Johnson & Johnson common stock received exchange offer recorded Treasury stock.",
  "item2": "Represents Federal State taxes includes TCJA foreign undistributed earnings payments $2.5 billion 2025 $2.0 billion 2024 Company access substantial sources funds numerous banks worldwide ability issue up $20 billion Commercial Paper. Furthermore, June 2025, Company secured new 364-day Credit Facility $10 billion (expiration June 24, 2026) which may used general corporate purposes including support commercial paper borrowings. Interest charged borrowings under credit line agreement based either Secured Overnight Financing Rate (SOFR) Reference Rate other applicable market rate allowed plus applicable margins. Commitment fees under agreement not material."
}